CD3 News and Research

RSS

Emerging cancer therapies and novel targets

What are the cancer drugs of tomorrow and how will they be developed? At the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, researchers will present some answers to these and other pressing questions regarding emerging cancer therapeutics.

25 Oct 2007

Lilly and MacroGenics to develop and commercialize teplizumab

Eli Lilly and Company and MacroGenics, Inc. have announced that the two companies have entered into a global strategic alliance to develop and commercialize teplizumab, a humanized anti-CD3 monoclonal antibody, as well as other potential next generation anti-CD3 molecules for use in the treatment of autoimmune diseases.

19 Oct 2007

Combinatorial approach found to reverse the onset of type 1 diabetes

A major finding, which represents an important step toward a potential cure for type 1 (insulin-dependent) diabetes, has been made by a research team at the La Jolla Institute for Allergy & Immunology (LIAI). The team, led by Matthias von Herrath, M.D., an internationally recognized expert on the molecular basis of type 1 diabetes, used a combinatorial treatment approach in laboratory mice and found it reversed recent onset type 1 diabetes in the majority of animals tested.

28 Apr 2006

Drug combo might beat type 1 diabetes

Scientists in California have developed a cocktail of drugs which can reverse diabetes and say the discovery is an important step towards a potential cure.

23 Apr 2006

Counseling for breast cancer patients means healthier diets, reduced smoking and stronger immune systems

Regular psychological counseling for breast cancer patients may do more than just lower their stress and anxiety. A new study says the right kind of intervention can also mean healthier diets, reduced smoking, and most surprising of all – a stronger immune system.

2 Sep 2004

Genetic trick makes gene therapy vectors more versatile

A genetic trick used by viruses to replicate themselves has been adapted for laboratory use to build complex protein structures required by immune system cells, according to investigators at St. Jude Children’s Research Hospital.

7 Apr 2004